Earnings Summary

Adma Biologics Inc’s revenue jumped 43.86% since last year same period to $81.88Mn in the Q1 2024. On a quarterly growth basis, Adma Biologics Inc has generated 10.79% jump in its revenue since last 3-months.

Adma Biologics Inc’s net profit jumped 239.5% since last year same period to $17.81Mn in the Q1 2024. On a quarterly growth basis, Adma Biologics Inc has generated 200.92% jump in its net profits since last 3-months.

Adma Biologics Inc’s net profit margin jumped 196.97% since last year same period to 21.75% in the Q1 2024. On a quarterly growth basis, Adma Biologics Inc has generated 191.09% jump in its net profit margins since last 3-months.

Adma Biologics Inc’s earning per share (EPS) estimates for the current quarter stand at 0.08 - a 33.33% jump from last quarter’s estimates.

Adma Biologics Inc’s earning per share (EPS) estimates for the current year stand at 0.08.

Adma Biologics Inc’s earning per share (EPS) jumped 366.67% since last year same period to 0.08 in the Q1 2024. This indicates that the Adma Biologics Inc has generated 366.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adma Biologics Inc’s return on assets (ROA) stands at 0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adma Biologics Inc’s return on equity (ROE) stands at -0.02.